Latest News

Research Update CHF 02723 EY2: Scientific and Clinical Assessment of Fecal Microbiota Transplant in Obese Dogs: SLIM Study

To date, we have screened (comprehensive physical examinations, bloodwork, and fecal analysis) 51 dogs for the SLIM study. Of these, 31 have met the inclusion criteria and were enrolled. Of these enrolled dogs, 23 dogs have completed the 24-week clinical trial and 2 dogs are currently enrolled (see Figure 1). Unfortunately, 6 dogs were removed from the study early with the most common reason related to administration of antimicrobials needed for underlying health conditions including dog bite wounds, urinary tract infections, and surgical procedures. Continue reading “Research Update CHF 02723 EY2: Scientific and Clinical Assessment of Fecal Microbiota Transplant in Obese Dogs: SLIM Study”

Research Update CHF 02686-A MY3: Pattern of Thyroid Function Tests during Recovery from Acute Nonthyroidal Illness

To date, 93 cases have been screened for possible study enrollment. Of these, 23 have fulfilled all of the enrollment criteria (92% of total cases needed) and are still in the study, 7 were enrolled but ultimately excluded (either determined to have a chronic disease, did not follow-up, or determined to have overt or subclinical hypothyroidism), 8 were not enrolled despite having a low total T4 (owner did not allow for study enrollment or found to have a chronic disease during diagnostic work-up), and 55 had a normal total T4 (failed to fulfill this inclusion criteria). Continue reading “Research Update CHF 02686-A MY3: Pattern of Thyroid Function Tests during Recovery from Acute Nonthyroidal Illness”

Research Update 02945-MOU EY1: Understanding the genetic basis of Addison’s disease in Portuguese Water Dogs

Over the first year of this study, we have focused primarily on sample collection. We collected samples mostly through PWD-related channels working directly with our collaborators in the PWDF/PWDCA. We also attended the PWD National Specialty in September 2021 to promote the study and collect samples, and we established a collaboration with Dr. Anita Oberbauer at UC Davis to share samples that she had already collected. Continue reading “Research Update 02945-MOU EY1: Understanding the genetic basis of Addison’s disease in Portuguese Water Dogs”

Research Update Final 02309-T: Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma

Lymphoma, particularly the large, B-cell subtype, is one of the most common malignancies in dogs. Canine lymphoma can be treated, but it is rarely cured. Novel therapeutic strategies are necessary to improve outcomes in dogs diagnosed with lymphoma. Continue reading “Research Update Final 02309-T: Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma”

Research Update CHF 02624 EY3: Embracing Polygenicity of Common Complex Disease in Dogs: Genome-wide Association of Cruciate Ligament Rupture

We have now completed recruitment and marker genotyping of Labrador Retriever dogs under this award. A final single nucleotide polymorphism (SNP) marker data set of 1,006 dogs has been assembled and filtered for data analysis, slightly exceeding what was promised under the award. Continue reading “Research Update CHF 02624 EY3: Embracing Polygenicity of Common Complex Disease in Dogs: Genome-wide Association of Cruciate Ligament Rupture”

Research Update CHF 02759 Mid-year 2: Reprogramming the Tumor Immune Niche in Canine Hemangiosarcoma

We have made significant progress toward Objective 1 and 2 for this project. Over the past six months, we have continued work to examine molecular and functional changes induced by PIK3CA gene mutations in canine HSA cells. Our data reveal that PI3K inhibitors increase DNA damage greater in HSA cells with PIK3CA mutations than cells without the mutations (i.e., wild-type cells), which depends on a drug dose. Continue reading “Research Update CHF 02759 Mid-year 2: Reprogramming the Tumor Immune Niche in Canine Hemangiosarcoma”

Research Update CHF 02428 EY-4: Identifying the Disease-Defining Autoantibodies in Canine Addison’s Disease

The goal of this project is to identify autoantibodies that are present in the blood of dogs who are newly diagnosed with Addison’s disease in three breeds: Standard Poodles, Portuguese Water Dogs, and English Cocker Spaniels. To accomplish these goals, we have been focusing on (1) collecting blood samples from dogs across all three target breeds, and (2) employing methods that allow us to detect these autoantibodies. Continue reading “Research Update CHF 02428 EY-4: Identifying the Disease-Defining Autoantibodies in Canine Addison’s Disease”

Research Update CHF 02783 EY2: Transcriptional Profiling of Canine Soft Tissue Sarcoma

Soft tissue sarcoma (STS) encompasses a number of neoplasms that are derived from mesenchymal cells including fibrosarcoma, myxosarcoma, hemangiopericytoma, and undifferentiated sarcoma. In the dog, STSs arise frequently in the dermis/subcutis and represent up to 15% of the neoplasms in this location. Our primary aim of this grant was to collect cases of canine STS for histologic and gene expression analysis. Continue reading “Research Update CHF 02783 EY2: Transcriptional Profiling of Canine Soft Tissue Sarcoma”

Research Update CHF 02534 MY 3 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

We opened the trial on July 1, 2019. As of June 27, 2021, we have enrolled 18 dogs in the study and no dose limiting toxicities within the initial 21-day assessment period have been observed. Based on these results, we are continuing to enroll dogs at the highest dose of propranolol (1.3 mg/kg) being tested. Continue reading “Research Update CHF 02534 MY 3 Update: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”